L-type calcium channel blocker suppresses calcineurin signal pathway and development of right ventricular hypertrophy

Journal of the Formosan Medical Association

Volumn 104, Issue 11, 2005, Pages 798-803

  Liu, Chen Zhou ^a   Tan, Jian Xin ^a   Wang, You ^a   Huang, Yu Ge ^a   Huang, Di Lan ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Amlodipine; Anoxia; Calcineurin; Hypertrophy, right ventricular; Signal transduction

Indexed keywords

AMLODIPINE; CALCINEURIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; MYOSIN; TRANSCRIPTION FACTOR NFAT; BMYO PROTEIN, RAT; MYOSIN HEAVY CHAIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; EXPERIMENTAL MODEL; HEART RIGHT VENTRICLE HYPERTROPHY; HYPOXIA; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; DRUG ANTAGONISM; GENETICS; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CALCINEURIN; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MYOSIN HEAVY CHAINS; NFATC TRANSCRIPTION FACTORS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 33645274695     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Groenendyk J, Lynch J, Michalak M: Calreticulin, Ca2+, and calcineurin - signaling from the endoplasmic reticulum. Mol Cells 2004;17:383-9.
2. Molkentin JD, Lu JR, Antos CL, et al: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-28.
3. Taigen T, De Windt L J, Lim HW, et al: Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A 2000;97:1196-201.
4. Zhu SJ, Yang YJ, Yu LJ, et al: CaN-NFAT3 signal pathway: a crucial hinge relates Ca2+ signal with cardiomyocyte hypertrophy. Zhonghua Nei Ke Za Zhi 2004;43:19-21. [In Chinese]
5. Wilkins BJ, Molkentin JD: Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol 2002;541:1-8.
6. Zou Y, Yamazaki T, Nakagawa K, et al: Continuous blockade of L-type Ca2+ channels suppresses activation of calcineurin and development of cardiac hypertrophy in spontaneously hypertensive rats. Hypertens Res 2002;25:117-24.
7. Xie ZZ, Liu FY, Wang SJ, et al: Preventive and therapeutive effects of nitrendipine on hypoxic right ventricular hypertrophy. Acta Pharmacologica Sinica 1996;17:337-40.
8. Takahashi T, Kanda T, Imai S, et al: Amlodipine inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Res Commun Mol Pathol Pharmacol 1996;91:17-32.
9. Rouet-Benzineb P, Eddahibi S, Raffestin B, et al: Induction of cardiac nitric oxide synthase 2 in rats exposed to chronic hypoxia. J Mol Cell Cardiol 1999;31:1697-708.
10. Ranger AM, Grusby MJ, Hodge MR, et al: The transcription factor NF-ATc is essential for cardiac valve formation. Nature 1998;392:186-90.
11. Sakata Y, Masuyama T, Yamamoto K, et al: Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation 2000;102:2269-75.
12. Tan JX, Liu CZ, Jie YL, et al: Effect of cyclosporine A on myocardial calcineurin activity of the right ventricle and plasma NO, nitric oxide synthase and endothelin-1 levels in rats with chronic hypoxia. Di Yi Jun Yi Da Xue Xue Bao 2004;24:656-8. [In Chinese]
13. Tan JX, Liu CZ, Wang Y, et al: Blockade of L-type Ca2+ channels suppresses activation of calcineurin and development of right ventricle cardiac hypertrophy induced by chronic hypoxia. Chinese J Pathophysiology 2004;20:1631-4. [In Chinese]